IZQVF Stock Recent News

Indivior Plc said on Friday its unit had agreed to pay $102.5 million to settle a lawsuit by multiple state attorneys general accusing it of using illegal tactics to shield its opioid addiction treatment Suboxone from generic competition.

Indivior PLC (OTCPK:INVVY) Q1 2023 Earnings Conference Call April 27, 2023 8:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Officer Ryan Preblick - Chief Financial Officer Conference Call Participants Paul Cuddon - Numis Securities Thibault Boutherin - Morgan Stanley Max Herrmann - Stifel Financial Corp Jason Thompson Good morning, good afternoon, everyone. Before we begin, I need to remind everyone that on today's call, we may make forward-looking statements that are subject to risks and uncertainties, and that actual results may differ materially.

Indivior PLC (LSE:INDV)'s solid fundamentals have been overshadowed by market concerns about a $290m legal provision, according to Jefferies. Despite the company's recent litigation troubles, Jefferies remains positive about the pharmaceutical firm's outlook.

Indivior PLC (OTCPK:INVVY) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Officer Ryan Preblick - Chief Financial Officer Conference Call Participants Thibault Boutherin - Morgan Stanley James Vane-Tempest - Jefferies Christian Glennie - Stifel Operator Good day and thank you for standing by. Welcome to the Indivior Plc Full Year Results 2022 Conference Call.

Drug company Indivior PLC (LSE:INDV)'s shares plummeted 13% after it set aside US$290mln for ongoing litigation in the states. It covers “multidistrict antitrust class and state claims” and follows legal action over its tactics to delay competition to its best-selling product, Suboxone, which is used to treat addiction.

Indivior PLC (LSE:INDV) shares have been given a price target of 2,655p by Jefferies, implying over 40% upside, after the company raised sales guidance for its Sublocade slow-release treatment for opioid addiction. Following last month's capital markets day update for investors, analysts at the investment bank said Sublocade's potential is “significantly greater” than their prior expectations, while the secondary listing on NASDAQ planned for spring 2023 is seen providing further support to the shares.

Indivior PLC (OTCPK:INVVY) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Mark Crossley - Chief Executive Officer Ryan Preblick - Chief Financial Officer Christian Heidbreder - Chief Scientific Officer Conference Call Participants Max Herrmann - Stifel Peter Testa - One Investments Mark Crossley Good morning, good afternoon and thanks for joining us. With me today to discuss our Second Quarter and Half Year Results are Ryan Preblick, our Chief Financial Officer; and Dr. Christian Heidbreder, our Chief Scientific Officer.

Indivior PLC (OTCPK:INVVY) Q1 2022 Results Earnings Conference Call April 28, 2022 8:00 AM ET Company Participants Mark Crossley - Chief Executive Officer Ryan Preblick - Chief Financial Officer Christian Heidbreder - Chief Scientific Officer Conference Call Participants Paul Cuddon - Numis Securities Thibault Boutherin - Morgan Stanley Max Herrmann - Stifel Institutional James Vane-Tempest - Jefferies Peter Testa - One Investments Operator Good day. And thank you for standing by.